Nuformix (LON:NFX) Shares Down 7.7% – Here’s What Happened

Nuformix plc (LON:NFX)’s stock price was down 7.7% during trading on Thursday . The company traded as low as GBX 0.23 and last traded at GBX 0.23. Approximately 1,843,170 shares changed hands during trading, a decline of 95% from the average daily volume of 33,943,625 shares. The stock had previously closed at GBX 0.25.

Nuformix Price Performance

The firm has a market cap of £5.49 million, a P/E ratio of -6.62 and a beta of 1.22. The stock’s 50 day moving average is GBX 0.26 and its two-hundred day moving average is GBX 0.23.

Nuformix (LON:NFX) last released its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.